

FIG. 1




FIG. 1 (cont.)




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

ApTOLL / ApTLR#4FT
(SEQ ID NO: 1)
GGTGTGCCAATAAACCATAT
CGCCGCGTTAGCATGTACTC
GGTTGGCCCTAAATACGAG






FIG. 7


Nerinetide (NA-1)



19% increase in 0-2 mRS
37% reduction in mortality

Only EVT patients without tPA
(Phase III ESCAPE-NA1 post-trial analysis)

ApTOLL



36% increase in 0-2 mRS
72% reduction in mortality

All EVT patients with or without tPA

FIG. 8




FIG. 9

